肺癌的常见肿瘤标志物和基因检测进展-文献综述

CRP。P＜0．01P＜0．05。DM2APN。4CRPAPNTNF-αTNF-αCRPAPNCRP。1965bonemorphogeneticproteinBMP。BMPBMP、。5。6BMPs。BMP-2P＜0．01P＜0．05。。7、。BMP-2CRP。、BMP-2BMP-2。BMP-2DM2。1．2J．2008325343376．2．C2J．2008514205-206．3VisserMBouterLMMcQuillanGMetal．ElevatedC-reactiveproteinlevelsinoverweightandobeseJ．JAMA1999282222131-2135．4．2C、J．2005216507-510．5．J．20072371003-1004．6CsiszarASmithKEKollerAetal．Regulationofbonemor-phogeneticprotein-2expressioninendothelialcellsroleofnuclearfac-tor-kappaBactivationbytumornecrosisfactor-alphaH2O2andhighin-travascularpressureJ．Circulation20051112364-2372．7．、-2J．2007154333-334．2012-07-23DOI10．3969/j．issn．1008-9810．2013．03．024323000潘炯伟曹卓**。20001100000。515%。。CEA、NSE、SCC、CYFRA21-1、CA125。。。11．1CarcinomaembryonicantigenCEACEA。CEACEA。CEAGold11965。、、、、、、CEACEA。CEA、CEA70%、—292—2013263JofRadioimmunology2013263Non-smallcelllungcancerNSCLCSmallcelllungcancerSCLCTNMCEA。CEACEA。Okada21926NSCLCCEA。CEA3。CEA。1．2Neuron-specificenolaseNSENSE。SCLCNSESCLC40%～70%65%～80%。4NSE＞10μg/L70%SCLCNSCLC20%。NSE＜12．5μg/L。NSESCLC。80%～96%NSENSE。SCLC24h～72hNSE。NSE。5NSENSCLC、NSESCLC。1．319Cytokeratinfragment19CY-FRA21-1CYFRA21-11940kDCK19。20。。CYFRA21-1、。6。CYFRA21-1。NSCLCCYFRA21-123%～70%Holdenrieder7128SCLC、Pro-GRP、CYFRA21-1NSECYFRA21-1。Koshiishi8CYFRA21-176．5%47．8%SCLC42．1%P＜0．01Ⅰ～Ⅳ60%、88．8%、80%100%。CY-FRA21-1SCLC47．1%P＜0．01CYFRA21-175%78．1%。CYFRA21-1SCLC。1．4SquamouscellcarcinomaantigenSCC-AgSCC-AgTA-414480001977Kato。SCC-Ag。An-do9312NSCLCCEA、TSGF、CYFRA21-1、CA125、SCC-Ag7112SCC-Ag55．4%。1．4%2．9%。CEASCC-AgCYFRA21-1。1．5125Carbohydrateantigen125CA125CA125CA12530%～61%34%～67%101990KimurallCA125CA125CA125。CA125NSCLC11CA125。12CA125NSCLC、。1．615-3Carbohydrateantigen15-3CA15-3CA15-3。CA15-3SCLCP＜0．0513。CA15-3、。1．719-9Carbohydrateantigen19-9CA19-9CA19-9KoprowskiBALB/c。CA19-9。CA19-9、、、、。13CA19-930%。CA19-9、、。22．1Epidermalgrowthfactorrecep-torEGFREGFRC-erb1。EGFR、。EGFREGFR。NSCLCEGFR40%～80%。EGFR、、。14、、EGFRTKIs。TKIsNSCLCEGFR—392—2013263JofRadioimmunology2013263。PCR14。EGFR。2．2TUM2-PKpyruvatekinasePK。PKM1、M2、L、R。。M2-PKPKR-PK、L-PK、M1-PK。Phos-phoenolpyru-vatePEPM2-PKM2-PK。M2-PKPEP。M2-PKM2-PKTUM2-PK。TUM2-PKTUM2-PKTUM2-PK。Schneidel、15-16、TUM2-PK。TUM2-PKSCLCNSCLC。SCLCNSCLCTUM2-PK。2．3DKK-1Dickkopf-1DKK-1WntWnt、、。Katase17DKK-110q11．2DKK-1266。DKK-1、、、17。、Chapman185。。Xi-ao19ELISA93NSCLC87DKK-162．0%84．0%。DKK-1。DKK-1、。DKK-1NSCLC。2．4GemininGeminin、。Gemi-nin1998。GemininHGemininL219216。GemininCDT1DNADNA20。GemininG1SSGemi-ninCDT1Pre-RCMCMDNAG2MAPCGeminin“”G121。GemininS/G2/M。Haruki22Geminin5100＜3cm。GemininGeminin。2．5inhibitorofapoptosisproteinsIAPSurvivin。Survivin。Survivin17q251447kb4314216．5kDa。Survivin。Survivin、、、。Survivin。Yagihashi23ELISA31NSCLCSurvivin58．1%。Survivin。Sur-vivinNSCLC。SurvivinSurvivin。2．6microRNAmicroRNA21～25ntRNA、。microR-NAmicroRNA、microRNA。Wang24miRNA-130aNSCLC。miRNA-130a、。miRNA-130a。CoxmiRNA-130aNSCLC25。2．7pro-GRPpro-GRPGRPGRP—492—2013263JofRadioimmunology2013263、。SCLCpro-GRP。pro-GRPSCLCTMNSE。LDSCLCNSESCLC、、。40pg/ml8．0μg/L26pro-GRP76%95%。pro-GRP①②③。31846Bence-Jones。、、、、。、。、20-21。TMNSCLCTM。TM。、ROC。1GoldPFreedmanSO．Demonstrationoftumorspecificantigeninhumancoloniccarcinomabyimmunologictoleranceandabsorptiontech-niquesJ．ExpMed1965127439-442．2OkadaMSakamotoTNishioWetal．Characteristicsandprogno-sisofpatientsafterresectionofnonsmallcelllungcarcinomameasuring2cmorlessingreatestdimensionJ．Cancer2003983535-541．3HigashiKSakumaTItoKetal．Combinedevaluationofpreop-eractiveFDGuptakeonPETground-glassopacityareaonCTandserumCEAlevelidentificationofbothlowandhighriskofrecurrenceinpa-tientswithresectedT1lungadenocarcinomaJ．EurNuclMedMolIma-ging2009363373-381．4SalsiVFerrariSFerraresiRetal．HOXD13bindsDNAreplica-tionoriginstopromoteoriginlicensingandisinhibitedbygemininJ．MolCellBiol200929215775-5788．5LouEJohnsonMLSimaCetal．Analysisofapanelofserumbio-markersinpatientswithmetastaticlungcancerJ．JClinOncol20102815180-184．6MolinaRAugeJMEscuderoJMetal．MucinsCA125CA19-9CA15-3andTAG72-3astumormarkersinpatientswithlungcancercomparisonwithCYFRA21-1CEASCC-AgandNSEJ．TumorBio2008296371-380．7HoldenriederSvonPawelJDankelmannEetal．NucleosomesProGRPNSECYFRA21-1andCEAinmonitoringfirst-linchemother-apyofsmallcelllungcancerJ．ClinCancerRes200814237813-7821．8KoshiishiHSakamotoKYasuraokaTetal．TworesectedcasesofpulmonaryadenocarcinomawithintralobermetastasisdiagnosedbythepathologicaldignosisduringtheoperationJ．GanToKagakuRyoho201037122735-2737．9AndoSKimuraHIwaiNeta1．Optimalcombinationofseventumormarkersinpredictionofadvancedstageatfirstexaminationofpa-tientswithnon-smallcel1lungcancerJ．AnticancerRes200121463085-3092．10ShitritDZingermanBShitritABetal．DiagnosticvalueofCY-FRA21-1CEACA19-9CA15-3andCA125assaysinpleuraleffusionsanalysisof116casesandreviewoftheliteratureJ．Oncologist2005107501-507．11．CA125J．2009315599-601．12．CA125、CEAJ．2008197-100．13．CEA、CA125、CA19-9J．20073181-182．14EberhardDAGiacconeGJohnsonBE．Biomarkersofresponsetoepidermalgrowthfactorreceptorinibitorsinnon-small-celllungcancerworkinggroupstandardizationforuseintheclinicaltrialsettingJ．ClinOncol2008266983-994．15SchneiderJSchulzeG．Comparisonoftumo